VBI Vaccines (VBIV) Hits Multi-Month High: What to do Now?

Over the past year, many companies that have been involved in developing COVID-19 vaccines have seen their stocks record significant gains. One of them is VBI Vaccines Inc (NASDAQ: VBIV), which is working on a COVID-19 vaccine as well. Over the course of the past month, the stock recorded gains of as much as 55%, and on Monday alone, it grew by 21%.

The latest rally in the stock could well be related to an update provided by the company back on January 23 with regards to its pair of COVID-19 vaccines. The vaccines in question are VBI 2901 and VBI 2902. VBI announced that VBI 2901 displayed strong immunogenicity and efficacy in a hamster challenge study.

Related:  QuikLAB Pushes TPT Global Tech (TPTW) To Soar More Than $1 Amid Growing Demand For COVID-19 Tests

On the other hand, the company announced that it is going to launch the Phase I/II study of the second vaccine VBI 2902 at some point in Q1 2021. These are major announcements and have resulted in considerable optimism in the markets.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.